Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MDL-101 is an experimental, epigenetic editing therapy, which is under investigation in the early-stage clinical trial studies for the treatment of LAMA2-congenital muscular dystrophy.
Lead Product(s): MDL-101
Therapeutic Area: Rare Diseases and Disorders Product Name: MDL-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2024
Details:
Modalis and JCR Pharmaceuticals aim to establish new gene therapies for undisclosed CNS diseases by applying J-Brain Cargo®, JCR Pharmaceuticals’ proprietary technology for crossing the blood-brain barrier, and CRISPR-GNDM®, Modalis proprietary epigenome modulation technology.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: JCR Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 12, 2023
Details:
MDL-101, an experimental, epigenetic modulation therapy, in preclinical data it supported durability and efficacy of a differentiated precision medicine approached for Congenital Muscular Dystrophy type 1a.
Lead Product(s): MDL-101
Therapeutic Area: Rare Diseases and Disorders Product Name: MDL-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022